Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients with Atrial Fibrillation: A Cohort Study
{{output}}
A 25% flecainide dose reduction has been recommended for intermediate metabolisers (IMs); however, studies have yielded contradictory results, likely due to the lack of standardisation in CYP2D6 pharmacogenetic classifications. We aimed to address this gap. Th... ...
